Oncology

Chronic myeloid leukaemia: from imatinib to asciminib

Unifarm pharmacists
Unifarm pharmacists
3 min read
Chronic myeloid leukaemia: from imatinib to asciminib
A blood smear under the microscope: CML treatment is monitored with blood counts and BCR-ABL levels.

In the 1990s chronic myeloid leukaemia (CML) was a fatal disease: without a bone marrow transplant most patients lived only a few years. Everything changed when imatinib arrived in 2001. Today CML is treated with tablets, and most patients diagnosed in the chronic phase live almost as long as their peers.

What happens in CML

In a blood-forming cell of the bone marrow, parts of two chromosomes — 9 and 22 — swap places. This creates the “Philadelphia chromosome” and a new gene, BCR-ABL1. It produces an enzyme that constantly tells cells to divide. The blood fills with too many white cells, the spleen grows, and weakness and sweating appear. Sometimes the disease is found by chance on a routine blood test.

Medicines: several generations

All CML medicines block the BCR-ABL enzyme. They are called tyrosine kinase inhibitors (TKIs).

Substance When it is used In the Unifarm catalogue
Imatinib First line, especially at low risk Imaxen 400
Dasatinib First line or if imatinib has not worked Sprycel 50, Dasanat 50
Nilotinib First line or if imatinib has not worked Knilonat 150
Ponatinib With the T315I mutation or after several medicines Ponaxen 45
Asciminib After two or more medicines, with the T315I mutation Ascimib 40

Second-generation medicines (dasatinib, nilotinib) work faster and deeper than imatinib but have their own side effects. Asciminib works differently: it binds to the enzyme at another site, so it helps when other medicines have stopped working. The haematologist chooses based on the disease phase, age, other conditions and mutations.

How treatment is monitored

The key test is a PCR blood test for BCR-ABL1. It shows how many diseased cells remain. It is usually done every 3 months, and less often once results are stable. The targets are:

  • at 3 months — no more than 10%;
  • at 6 months — no more than 1%;
  • at 12 months — 0.1% or less (called a major molecular response).

If the targets are not met, the doctor checks whether the medicine is being taken regularly and looks for mutations that may stop it working. Then the medicine is changed.

Taking it regularly is the key to success

CML treatment lasts for years, and missed tablets are a common reason it stops working. A phone alarm and a weekly pill box help. It is also important that:

  • nilotinib is taken on an empty stomach: no food for 2 hours before and 1 hour after;
  • you avoid grapefruit juice and St John’s wort — they change the level of the medicine in the blood;
  • you tell your haematologist about any new medicines.

Side effects

  • Imatinib: swelling around the eyes, muscle cramps, nausea.
  • Dasatinib: fluid around the lungs — report shortness of breath to your doctor right away.
  • Nilotinib: higher blood sugar and cholesterol, effects on blood vessels and the heart.
  • Ponatinib: a risk of blood clots, so blood pressure and vessels are monitored.

Can treatment be stopped?

Yes, for some patients. If treatment has lasted several years and BCR-ABL has stayed very low for a long time, the haematologist may suggest stopping under close monitoring, with a monthly test at first. In about half of these patients the disease does not come back. If the level rises again, the medicine is restarted and usually works again. Never stop treatment on your own.

This article is for information only. CML treatment is prescribed and monitored by a haematologist.

Notice. The information in this article is for reference only and does not replace medical consultation. Always consult a healthcare professional before using any medication.

Mentioned medications

Related articles

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00